Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Vitamin K Antagonists Versus Low‐molecular‐weight Heparin for the Long Term Treatment of Symptomatic Venous Thromboembolism." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/images/closex.png. Accessed 27 April 2024.
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/images/closex.png. Accessed April 27, 2024.
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/images/closex.png
Vitamin K Antagonists Versus Low‐molecular‐weight Heparin for the Long Term Treatment of Symptomatic Venous Thromboembolism [Internet]. In: Cochrane Abstracts. [cited 2024 April 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/images/closex.png.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
ID - 433496
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/images/closex.png
DB - Evidence Central
DP - Unbound Medicine
ER -